Further contributing to QTP susceptibility, polymorphisms in the angiotensin-converting enzyme and angiotensin II type 1 receptor genes contribute additively to QTP, which is prevalent in the majority of end-stage renal disease patients [28]. This evidence concerns the gene ACE and stage 5 chronic kidney disease.